Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · bladder-landscape@3

SRR8943045

—

b8930b25-0dab-579f-8a14-9602461c150d

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • G2M_CHECKPOINT+0.480
  • MYC_TARGETS_V1+0.450
  • MYC_TARGETS_V2+0.450
  • E2F_TARGETS+0.410
  • PROTEIN_SECRETION+0.380
  • ANGIOGENESIS+0.350
  • MTORC1_SIGNALING+0.350
  • UNFOLDED_PROTEIN_RESPONSE+0.340
  • MITOTIC_SPINDLE+0.240
  • TNFA_SIGNALING_VIA_NFKB+0.220

Top 10 suppressed

  • WNT_BETA_CATENIN_SIGNALING-0.330
  • P53_PATHWAY-0.260
  • KRAS_SIGNALING_DN-0.240
  • HEME_METABOLISM-0.230
  • HEDGEHOG_SIGNALING-0.210
  • NOTCH_SIGNALING-0.210
  • BILE_ACID_METABOLISM-0.190
  • ESTROGEN_RESPONSE_EARLY-0.190
  • ESTROGEN_RESPONSE_LATE-0.190
  • APICAL_JUNCTION-0.170

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1C3N-00294
lung-landscapes@6
—cohortA10.814
2274656
medullo-epn-umap@date-based
EPNEPN Tumor0.805
34d36189e-fe88-4cfb-970b-a51b8e9e0783
melanoma-umap@29
——0.788
4SRR8518311
breast-umap@18
—E0.781
5MNG732
mng-umap@100
——0.778
6SRR12202405
bladder-landscape@3
——0.769
7s0122158
melanoma-umap@29
——0.769
8TCGA-05-4415-01A-22R-1858-07
lung-landscapes@6
—cohortA40.768
9SRR934912
brain-umap@2
——0.767
10MDT-AP-0599
medullo-epn-umap@date-based
MedMedulloblastoma0.765

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 25 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
G2M_CHECKPOINT0.480Inavolisib— uncovered
MYC_TARGETS_V10.450Inavolisib— uncovered
MYC_TARGETS_V20.450Idelalisib— uncovered
E2F_TARGETS0.410Inavolisib— uncovered
PROTEIN_SECRETION0.380Remibrutinib— uncovered
ANGIOGENESIS0.350Remibrutinib— uncovered
MTORC1_SIGNALING0.350Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.340Idelalisib— uncovered
MITOTIC_SPINDLE0.240Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.220Inavolisib— uncovered
INTERFERON_ALPHA_RESPONSE0.180Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.170Idelalisib— uncovered
TGF_BETA_SIGNALING0.150Inavolisib— uncovered
PANCREAS_BETA_CELLS0.140Cobimetinib— uncovered
PI3K_AKT_MTOR_SIGNALING0.140Inavolisib— uncovered
SPERMATOGENESIS0.140Inavolisib— uncovered
ANDROGEN_RESPONSE0.120Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.120Remibrutinib— uncovered
UV_RESPONSE_UP0.120Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.100Inavolisib— uncovered